AbbVie Loses Second Consecutive Bellwether Suit Over AndroGel Risks

Drug Industry Daily
A A
A jury awarded $140 million to the plaintiff in a suit against AbbVie over its testosterone replacement drug AndroGel.

To View This Article:

Login

Subscribe To Drug Industry Daily